Insulin Resistance as a Cardiovascular Risk Factor
Keywords:
blood pressure, hyperlipidemia, obesity, diabetes mellitusAbstract
However, the literature on the role of NTG as RF CHD differs significantly. Meanwhile, in some cases, NTG can precede the development of DM and, in a certain sense, it can be considered as a state of "pre-disease" in relation to DM. Hyperglycemia, including latent hyperglycemia, often proceeds with hyperinsulinemia, which is considered one of the components of the "metabolic" syndrome that plays an important role in the formation of cardiovascular diseases. including coronary artery disease.
References
Agzamova, G. S., Abdieva, Y. A., Tashmukhamedova, M. K., & Kenzhabaev, D. (2024). Features of the clinical course of silicosis in combination with coronary heart disease and arterial hypertension.
Akbarova M., Mamasoliev N.S. Epidemiological, clinical, biorhythmological and preventive aspects of chronic heart failure in the conditions of the sharply continental climate of the Fergana Valley/V-Congress of Cardiologists of the CIS countries in the journal Cardiology of the CIS. 2005, vol.-3, No 2, art. 17.
Rakhmatova, D. B. (2019). Analysis of the risk factors of Chd in persons over 60 years among the population of the city of Bukhara. Asian studies. Индия, 1, 33-38.
Rakhmatova, D. B. (2019). Main" symptoms and leading clinical variants of the course of acute coronary syndrome in women. Journal of Biomedicine and Practice, 2(6), 68-73.
Tursunov Kh.Kh., Babich S.M. Features of the Coronary Heart Disease Flow in the Conditions of the Sharply Continental Climate of the Fergana Valley of Uzbekistan. – 2008. – No 3 – P. 31-34
Kamilova U.K., Rasulova Z.D. Study of the comparative efficacy of losartan and lisinopril on glomerulo-tubular markers of renal dysfunction in patients with chronic heart failure. Cardiovascular therapy and prevention. 2015; 14(2):41-45. https://doi.org/10.15829/1728-8800-2015-2-41-45
Shagazatova B.Kh., Assessment of the quality of outpatient and polyclinic observation of patients with diabetes mellitus // Vrachebnoye delo, 2013.
American Diabetes Association. Prevention or delay of the development of type 2 diabetes mellitus. Diabetes treatment. 2017; 40 (Appendix 1): C44–C47.
Asprey, K.E., Van Horn, L., Carson, J.A., et al.: Medical Nutrition Education, Training, and Competencies to Advance Guideline-Based Nutritional Counseling by Physicians: Scientific Advice from the American Heart Association. Circulation. 2018; 137(23): e821–e841. 10.1161/CIR.000000000000000563.
Barrett-Connor E, Howe K.T. Diabetes Mellitus: An Independent Risk Factor for Stroke? Am J Epidemiol 1988; 128:116–23. 10.1093/oxfordjournals.aje.a114934
Stumwall M., Goldstein B.J., van Heften T.V. Type 2 diabetes mellitus: principles of pathogenesis and therapy. Lancet. 2005; 365(9467):1333–46.
Fed, E. S., Giles, W. H. & Dietz, W. H. Prevalence of metabolic syndrome among adults in the United States: results from the third National Health and Nutritin Survey. JAMA 287, 356–359 (2002).
Teixeira T.F., Alves RD, Moreira A., Pelutsio Mdo S. Main characteristics of metabolic obesity of normal weight and metabolically healthy phenotypes of obesity. Nutr Rev. 2015; 73:175–190.
Zinman B, Wanner S, Lachin J.M. etc.; EMPAREG OUTCOME researchers. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes mellitus. N Engl J Med. 2015; 373:2117–2128.
Long-term pioglitazone treatment of patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016; 165:305–315.
Kahn R., Buse J., Ferrannini E., Stern M. Metabolic syndrome: time for critical assessment. Joint statement by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetology. 2005; 48(9):1684–99.
Grandi SM, Kliman JI, Daniels SR, Donato CA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage J, Smith SC, et al. Diagnosis and treatment of metabolic syndrome: a scientific statement from the American Heart Association/National Heart, Lung, and Blood Institute. Circulation. 2005; 112(17):2735–52.
Lu I, Hajifatalian K, Ezzati M, et al. Metabolic mediators of the effects of body mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet 2014; 383:970–83. 10.1016/S0140-6736(13)61836-X.
